GlassScriptPhysician profile
Frederick James Neher
NPI 1295470763
$1,728.53
in general payments reported to CMS, 2019-2025
13 companies · $1,008 in 2025
The $1,008 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $266 · 2024: $455 · 2025: $1,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,724 · Education: $4.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,723.75 |
| Education | $4.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $296.54 | 2023-2025 | |
| Dompe US, INC. | $269.79 | 2023-2025 | Oxervate |
| Harrow Eye, LLC | $225.83 | 2024-2025 | Vevye |
| Bausch & Lomb Americas INC. | $207.31 | 2024-2025 | Vyzulta, Miebo, Xiidra |
| Tarsus Pharmaceuticals, INC. | $186.99 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $170.84 | 2025 | Rocklatan, Tryptyr, Eysuvis |
| Sun Pharmaceutical Industries INC. | $169.46 | 2023-2025 | Cequa |
| Rxsight INC | $61.35 | 2023-2025 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Amgen INC. | $46.64 | 2025 | Tepezza |
| Glaukos Corporation | $36.94 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Thea Pharma INC. | $24.59 | 2025 | Iyuzeh |
| Abb Con-Cise Optical Group LLC | $17.90 | 2025 | Contact Lens, Spectacle Lenses |
| Sight Sciences, INC. | $14.35 | 2025 | Tearcare System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Neher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.